Intra-Cellular Therapies (NASDAQ:ITCI) Receives Neutral Rating from Cantor Fitzgerald

Intra-Cellular Therapies (NASDAQ:ITCI)‘s stock had its “neutral” rating reissued by Cantor Fitzgerald in a note issued to investors on Wednesday,Benzinga reports. They presently have a $132.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price points to a potential upside of 0.07% from the stock’s current price.

A number of other analysts have also recently weighed in on the stock. Mizuho cut shares of Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $140.00 to $132.00 in a research report on Monday, February 24th. Leerink Partnrs downgraded shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Royal Bank of Canada reissued a “sector perform” rating and set a $132.00 target price (up from $108.00) on shares of Intra-Cellular Therapies in a research report on Wednesday, January 22nd. Piper Sandler reaffirmed a “neutral” rating and set a $132.00 price target (up previously from $107.00) on shares of Intra-Cellular Therapies in a research note on Tuesday, January 14th. Finally, Needham & Company LLC restated a “hold” rating on shares of Intra-Cellular Therapies in a research note on Friday, February 21st. Eleven research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Intra-Cellular Therapies has a consensus rating of “Hold” and a consensus target price of $106.23.

Intra-Cellular Therapies Price Performance

ITCI stock traded down $0.01 during trading on Wednesday, reaching $131.91. 16,042,154 shares of the stock traded hands, compared to its average volume of 1,460,295. The business’s 50 day moving average price is $129.34 and its 200-day moving average price is $100.60. The firm has a market capitalization of $14.05 billion, a PE ratio of -151.62 and a beta of 0.69. Intra-Cellular Therapies has a 52-week low of $64.09 and a 52-week high of $131.98.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). The business had revenue of $199.22 million for the quarter, compared to analyst estimates of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. On average, equities research analysts predict that Intra-Cellular Therapies will post -0.64 earnings per share for the current year.

Institutional Trading of Intra-Cellular Therapies

A number of large investors have recently modified their holdings of the company. MassMutual Private Wealth & Trust FSB increased its stake in shares of Intra-Cellular Therapies by 124.3% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 133 shares during the period. M&T Bank Corp increased its holdings in shares of Intra-Cellular Therapies by 2.2% during the fourth quarter. M&T Bank Corp now owns 6,301 shares of the biopharmaceutical company’s stock valued at $526,000 after purchasing an additional 138 shares during the period. Wealth Enhancement Advisory Services LLC lifted its holdings in Intra-Cellular Therapies by 1.6% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 8,951 shares of the biopharmaceutical company’s stock worth $748,000 after purchasing an additional 141 shares during the period. CIBC Asset Management Inc grew its position in Intra-Cellular Therapies by 5.3% in the 4th quarter. CIBC Asset Management Inc now owns 2,956 shares of the biopharmaceutical company’s stock valued at $247,000 after buying an additional 150 shares in the last quarter. Finally, Pallas Capital Advisors LLC increased its stake in Intra-Cellular Therapies by 6.4% during the 4th quarter. Pallas Capital Advisors LLC now owns 3,182 shares of the biopharmaceutical company’s stock valued at $266,000 after buying an additional 192 shares during the period. Institutional investors and hedge funds own 92.33% of the company’s stock.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.